A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females

July 8, 2019 updated by: Hofseth Biocare ASA

A Proof-of-concept Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females

The objective of this study is to evaluate the efficacy of Salmon Protein Hydrolysate Powder (CollaGo®) on energy increase and anti-inflammatory modulation in healthy males and females. Eligible participants will be asked to consume 1 sachet of CollaGo for 128 days and keep a study diary. Assessments will be measured at the randomization visit, and the end of study visit.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • London, Ontario, Canada, N6A 5R8
        • KGK Science Inc.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Healthy male or female, 30-60 years of age
  2. Female participant is not of child bearing potential, defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) or,

    Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
    • Double-barrier method
    • Intrauterine devices
    • Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner (shown successful as per appropriate follow-up)
  3. BMI of 18.5 kg/m²-32.5 kg/m²
  4. Agrees to comply with study procedures
  5. Willing to commit to taking product for 128 days
  6. Agrees to provide voluntary, written, informed consent to participate in the study
  7. Agrees to maintain normal diet and exercise routine throughout the study
  8. Healthy as determined by medical history, medical physical test for good health, and laboratory results

Exclusion Criteria:

  1. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
  2. Blood donation during or within 30 days of the last study visit
  3. Taking any specific energy supplements or vitamins at least 1 month prior to and during the trial as assessed by the QI
  4. Unstable weight for the last 2 months prior to the study assessed case by case by QI
  5. Individuals on a low protein diet
  6. Excessive consumption of alcohol equivalent to >2 alcoholic drinks/day
  7. Use of marijuana assessed case by case by QI
  8. Known allergy to the test material's active or inactive ingredients
  9. Clinically significant abnormal Physical Examination results at screening
  10. Participation in clinical trials in the past 30 days
  11. Cognitively impaired and/or unable to give informed consent
  12. current cardiovascular disorders or uncontrolled blood pressure will be assessed by QI)
  13. Verbal confirmation of history of or current diagnosis of bleeding/blood disorder
  14. Verbal confirmation of Type I or Type II diabetes
  15. Verbal confirmation of kidney disease
  16. Verbal confirmation of history of liver disease
  17. Anemia based on hemoglobin and hematocrit at screening
  18. Thyroid disease assessed case by case by QI
  19. Iron Supplementation
  20. Mood stabilizers assessed case by case by QI
  21. Energy boosting supplements
  22. Individuals on workout supplements
  23. Habitual users of energy drinks
  24. Melatonin supplementation assessed case by case by QI
  25. Autoimmune disease or if immune-compromised (i.e. HIV positive, use of anti-rejection medication, rheumatoid arthritis, Hepatitis B/C positive)
  26. Surgical procedures which may impact the study outcomes within the past 3 months to be assessed by the QI
  27. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission will be assessed by the QI for inclusion.
  28. Presence or history of neurological disorders or significant psychiatric illness as assessed by QI
  29. Any other condition, in the QI's opinion, which may adversely affect the participant's ability to complete the study or its measures or which may pose significant risk to the participant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Salmon Protein Hydrolysate (CollaGo®)
Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.
4g of salmon protein hydrolysate per serving.
Other Names:
  • CollaGo®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Change From Baseline (Day 0) to End-of-study (Day 128) in Energy Level After a 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)

This questionnaire consists of a total of 30 questions that assess vitality and quality of life. The responses for these questions range from 1 to 7, where 1 indicates "never" or "not at all true" 4 indicates "sometimes" or "somewhat true" and 7 indicates "always" or "very true" depending on the item that is assessed by the question.

15 of the 30 questions are positively keyed in which a higher score indicates a better outcome and remaining 15 questions are negatively keyed where a lower score indicates a better outcome. The responses on the negatively keyed questions will be reversed prior to calculating the total score (i.e. a response of 1 will be considered as 7, 2 will be considered as 6, etc.). Total range will be 30-210, where a higher total score indicates a better outcome and a lower total score indicates a worse outcome.

Baseline (Day 0) to end-of-study (Day 128)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline to Day 128 in Red Blood Cell (RBC) Count After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Mean Corpuscular Volume (MCV) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin (MCH) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin Concentration (MCHC) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Hematocrit After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Red Cell Distribution Width (RDW) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Hemoglobin (Hb) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Relative Expression of 84 Stress Genes After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Evaluated by oxidative stress-related gene RT Profiler PCR array. Seven of the 84 genes were upregulated, which are highlighted in the results.
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Total Reactive Oxygen Species/Reactive Nitrogen Species Free Radical Activity After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Assessed by ROS/RNS assay
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-1 Alpha After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Measured by the Multi-Analyte ELISArray
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-4 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Measured by the Multi-Analyte ELISArray
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-6 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Measured by the Multi-Analyte ELISArray
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-10 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Measured by the Multi-Analyte ELISArray
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-11 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Measured by the Multi-Analyte ELISArray.
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-13 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Measured by the Multi-Analyte ELISArray
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine TGF-Beta After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Measured by the Multi-Analyte ELISArray
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Glycated Hemoglobin (HbA1c) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Fasting Glucose After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
Change in Score of the Hair, Nails, and Skin Self-Assessment Questionnaire After 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)

This questionnaire consists of a total of 7 questions that assess the participant's perception on hair (4 questions), nail (1 question) and skin health (2 question). The response to each question can range from 1 to 6 where 1 indicates "greatly satisfied" and 6 indicates "greatly dissatisfied".

The range for the total score on this questionnaire is 7-42. Lower total score indicates a better outcome, and higher total score indicates a worse outcome.

Baseline (Day 0) to end-of-study (Day 128)

Other Outcome Measures

Outcome Measure
Time Frame
The Incidence of Adverse Events Following a 128-day Supplementation
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Weight
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Blood Pressure
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Heart Rate
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Waist Circumference
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Hip Circumference
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
Baseline (Day 0) to end-of-study (Day 128)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 5, 2018

Primary Completion (Actual)

October 23, 2018

Study Completion (Actual)

October 23, 2018

Study Registration Dates

First Submitted

May 14, 2018

First Submitted That Met QC Criteria

May 23, 2018

First Posted (Actual)

May 24, 2018

Study Record Updates

Last Update Posted (Actual)

August 19, 2019

Last Update Submitted That Met QC Criteria

July 8, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Salmon Protein Hydrolysate

3
Subscribe